Organization
Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain
1 abstract
Abstract
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.Org: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quirón, UVic-UCC, Barcelona, Spain, Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain, Sarah Cannon Research Institute UK, London, United Kingdom, Florida Cancer Specialists and Research Institute, Lakewood Ranch, FL,